Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity.
hepatocellular carcinoma
molecular profiling
skin lesions
treatment adverse events
tyrosine kinase inhibitors
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
02 Mar 2021
02 Mar 2021
Historique:
received:
05
01
2021
accepted:
01
02
2021
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
23
3
2021
Statut:
epublish
Résumé
Dermatological adverse events (DAE) in hepatocellular carcinoma (HCC) patients treated with sorafenib predicts better outcome. Some turn into skin lesions (SL) requiring pathology examination. We describe incidence, characteristics and molecular profile of SL in HCC patients treated with sorafenib. SL were prospectively collected in 311 HCC patients who started sorafenib. SL from sorafenib cohort were compared to those from a control patient group selected to match SL type and demographics. Eighty-eight out of 311 patients developed DAE and 7.4% SL required histological assessment. Most frequent lesions were keratoacanthomas ( The onset of SL and their molecular profile did not impact negatively on patient's prognosis, but intense proliferation of SL may reflect compensatory activation of MAPK pathway and warrants their close monitoring.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Dermatological adverse events (DAE) in hepatocellular carcinoma (HCC) patients treated with sorafenib predicts better outcome. Some turn into skin lesions (SL) requiring pathology examination. We describe incidence, characteristics and molecular profile of SL in HCC patients treated with sorafenib.
MATERIALS AND METHODS
METHODS
SL were prospectively collected in 311 HCC patients who started sorafenib. SL from sorafenib cohort were compared to those from a control patient group selected to match SL type and demographics.
RESULTS
RESULTS
Eighty-eight out of 311 patients developed DAE and 7.4% SL required histological assessment. Most frequent lesions were keratoacanthomas (
CONCLUSIONS
CONCLUSIONS
The onset of SL and their molecular profile did not impact negatively on patient's prognosis, but intense proliferation of SL may reflect compensatory activation of MAPK pathway and warrants their close monitoring.
Identifiants
pubmed: 33747359
doi: 10.18632/oncotarget.27891
pii: 27891
pmc: PMC7939531
doi:
Types de publication
Journal Article
Langues
eng
Pagination
440-449Informations de copyright
Copyright: © 2021 da Fonseca et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Leonardo G. da Fonseca: None. -Carla Fuster-Anglada: None. -Cristina Carrera: None. Cristina Millán: None. - Esther Samper: None. Víctor Sapena: Travel funding from Bayer. Álvaro Díaz-González: Speaker fees and travel funding from Bayer. Travel funding from BTG and GILEAD. Marco Sanduzzi-Zamparelli: Speaker fees and travel funding from Bayer. Travel grant from BTG. Alejandro Forner: Consultancy fees from Bayer, Guerbert, AstraZeneca. Speaker fees from Bayer, MSD-Eisai and Gilead. Jordi Bruix: Consultancy fees from Arqule, Bayer, Novartis, BMS, BTGBiocompatibles, Eisai, Kowa, Terumo, Gilead, Bio-Alliance/Onxeo, Roche, AbbVie, Merck, Sirtex, Ipsen, Astra-Medimmune, Incyte, Quirem, Adaptimmune, Lilly, Basilea, Nerviano. Research grants from Bayer and BTG. Educational grants from Bayer and BTG. Lecture fees from Bayer, BTG- Biocompatibles, Eisai, Terumo, Sirtex, Ipsen. María Reig: Consultancy fees from Bayer, BMS, Roche, Ipsen, AstraZeneca and Lilly. Lecture fees from Bayer, BMS, Gilead, and Lilly. Research grants from Bayer and Ipsen. Loreto Boix: None. Alba Díaz: None.
Références
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Dermatol Surg. 2013 Jul;39(7):981-7
pubmed: 23464361
Curr Opin Oncol. 2011 Mar;23(2):177-82
pubmed: 21192261
Dermatol Surg. 2009 Nov;35(11):1766-70
pubmed: 19660024
J Invest Dermatol. 2014 Oct;134(10):2630-2638
pubmed: 24662767
Dermatology. 2010;221(3):193-6
pubmed: 20720388
Cold Spring Harb Perspect Biol. 2013 Feb 01;5(2):
pubmed: 23378590
Urol Int. 2013;91(4):482-3
pubmed: 23969404
Best Pract Res Clin Haematol. 2009 Mar;22(1):115-28
pubmed: 19285278
J Clin Oncol. 2012 Jan 20;30(3):316-21
pubmed: 22067401
JAMA Dermatol. 2014 Oct;150(10):1063-71
pubmed: 25103031
N Engl J Med. 2007 Jan 11;356(2):125-34
pubmed: 17215530
Nat Rev Clin Oncol. 2013 Jul;10(7):390-9
pubmed: 23712190
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
J Am Acad Dermatol. 2007 Jan;56(1):171-2
pubmed: 17190642
Clin Genitourin Cancer. 2009 Jan;7(1):20-3
pubmed: 19213663
Cancer. 2017 Apr 1;123(7):1184-1193
pubmed: 27906449
Mod Pathol. 2011 Sep;24(9):1248-53
pubmed: 21552211
Science. 2015 May 22;348(6237):880-6
pubmed: 25999502
Mod Pathol. 2015 Jun;28(6):799-806
pubmed: 25676557
J Hepatol. 2014 Aug;61(2):318-24
pubmed: 24703956
Oncologist. 2014 Mar;19(3):251-8
pubmed: 24563075
JAMA Dermatol. 2015 Oct;151(10):1103-9
pubmed: 26200476
Aliment Pharmacol Ther. 2019 Mar;49(5):482-491
pubmed: 30695819
N Engl J Med. 2018 Dec 20;379(25):2417-2428
pubmed: 30575484
Clin Cancer Res. 2012 Jan 1;18(1):263-72
pubmed: 22096025
Clin Cancer Res. 2014 Dec 15;20(24):6582-92
pubmed: 25303977
J Clin Oncol. 2009 Aug 10;27(23):e59-61
pubmed: 19597016
Nature. 2010 Mar 18;464(7287):431-5
pubmed: 20130576
World J Surg Oncol. 2012 Feb 29;10:47
pubmed: 22376079
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14025-9
pubmed: 8943054
Cancer Res. 2014 Sep 15;74(18):4967-75
pubmed: 25172843
J Natl Cancer Inst. 2008 Feb 20;100(4):282-4
pubmed: 18270341
Exp Dermatol. 2016 Feb;25(2):85-91
pubmed: 26476131
N Engl J Med. 2012 Jan 19;366(3):207-15
pubmed: 22256804
Indian J Dermatol. 2013 May;58(3):181-7
pubmed: 23723466
Nat Rev Cancer. 2014 Jul;14(7):455-67
pubmed: 24957944
Ann Hepatol. 2017 Feb 15;16(2):263-268
pubmed: 28233750